Reviva Pharmaceuticals Holdings Inc. Net Assets
Reviva Pharmaceuticals Holdings Inc. net assets. Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc. (RVPH) has net assets worth $15.21 Trillion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.14 Trillion) and total liabilities ($5.93 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Reviva Pharmaceuticals Holdings Inc. net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.21 Trillion |
| % of Total Assets | 71.93% |
| Annual Growth Rate | -24.02% |
| 5-Year Change | -69.85% |
| 10-Year Change | N/A |
| Growth Volatility | 395.46 |
Net Assets of Reviva Pharmaceuticals Holdings Inc. (2018–2025)
Net assets of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025. This chart illustrates how Reviva Pharmaceuticals Holdings Inc.'s net assets have evolved over time, based on quarterly financial data. See RVPH net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Reviva Pharmaceuticals Holdings Inc. (2018–2025)
The table below shows the annual net assets of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025. For live market cap and overall valuation, see market cap of Reviva Pharmaceuticals Holdings Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $8.65 Million | +964.23% |
| 2024-12-31 | $812.57K | -85.79% |
| 2023-12-31 | $5.72 Million | -31.87% |
| 2022-12-31 | $8.39 Million | -70.74% |
| 2021-12-31 | $28.69 Million | +424.84% |
| 2020-12-31 | $5.47 Million | +180.24% |
| 2019-12-31 | $-6.81 Million | -111.51% |
| 2018-12-31 | $59.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Reviva Pharmaceuticals Holdings Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13045807900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Reviva Pharmaceuticals Holdings Inc. Net Assets Breakdown (December 2025)
Reviva Pharmaceuticals Holdings Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.65K | 0.13% |
| Other Components | $192.77 Million | 2229.21% |
| Total Equity | $8.65 Million | 100.00% |
Reviva Pharmaceuticals Holdings Inc. Competitors by Market Cap
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GIGLIO.COM S.P.A. O.N.
F:5JR0
|
$6.29 Million |
|
Identi Healthcare Ltd
TA:IDNT
|
$6.30 Million |
|
Argentina Lithium & Energy Corp
V:LIT
|
$6.31 Million |
|
Citra Nusa Holdings Bhd
KLSE:5104
|
$6.31 Million |
|
Maschinenfabrik HEID AG
VI:HED
|
$6.29 Million |
|
J-Long Group Limited
NASDAQ:JL
|
$6.29 Million |
|
Encres Dubuit SA
PA:ALDUB
|
$6.29 Million |
|
Rossi Residencial S.A
SA:RSID3
|
$6.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Reviva Pharmaceuticals Holdings Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 812,572 to 8,647,645, a change of 7,835,073 (964.2%).
- Net loss of 19,864,902 reduced equity.
- New share issuances of 18,632,318 increased equity.
- Other factors increased equity by 9,067,657.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.86 Million | -229.71% |
| Share Issuances | $18.63 Million | +215.46% |
| Other Changes | $9.07 Million | +104.86% |
| Total Change | $- | 964.23% |
Book Value vs Market Value Analysis
This analysis compares Reviva Pharmaceuticals Holdings Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.20x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $580.05 | $0.48 | x |
| 2019-12-31 | $-49.17 | $0.48 | x |
| 2020-12-31 | $35.70 | $0.48 | x |
| 2021-12-31 | $38.79 | $0.48 | x |
| 2022-12-31 | $8.60 | $0.48 | x |
| 2023-12-31 | $4.81 | $0.48 | x |
| 2024-12-31 | $0.49 | $0.48 | x |
| 2025-12-31 | $2.38 | $0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Reviva Pharmaceuticals Holdings Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -229.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.84x
- Recent ROE (-229.71%) is above the historical average (-623.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -2.84% | 0.00% | 0.00x | 1.10x | $-7.60 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-165.69K |
| 2020 | -69.22% | 0.00% | 0.00x | 1.60x | $-4.33 Million |
| 2021 | -29.71% | 0.00% | 0.00x | 1.09x | $-11.39 Million |
| 2022 | -289.95% | 0.00% | 0.00x | 2.25x | $-25.18 Million |
| 2023 | -686.53% | 0.00% | 0.00x | 4.14x | $-39.83 Million |
| 2024 | -3681.99% | 0.00% | 0.00x | 19.08x | $-30.00 Million |
| 2025 | -229.71% | 0.00% | 0.00x | 1.84x | $-20.73 Million |
Industry Comparison
This section compares Reviva Pharmaceuticals Holdings Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $-1,986,338
- Average return on equity (ROE) among peers: -54.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Reviva Pharmaceuticals Holdings Inc. (RVPH) | $15.21 Trillion | -2.84% | 0.39x | $6.29 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $15.17 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $-10.50 Million | 0.00% | 0.00x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.55 Billion |
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, s… Read more